



## **Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance**

*Joins trade associations and over 100 pharmaceutical, biotech and diagnostic companies to call for collective action and government support to tackle crisis*

**Copenhagen, Denmark – 18<sup>th</sup> January 2017** – Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections, has signed *The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)*, announced today at the World Economic Forum Annual Meeting in Davos, Switzerland.

Xellia joins international industry associations and over 100 leading pharmaceutical, biotech, diagnostic and generic drug companies in signing the "Davos Declaration" which was first published on 21 January 2016. This joint Declaration calls for collective action against the global crisis of AMR, including increased investment and support from government.

Carl-Åke Carlsson, CEO, Xellia said: "Antimicrobial resistance is a huge global issue and an immense challenge to overcome. As a leading supplier of specialty antibiotics, such as vancomycin and colistimethate sodium (CMS) that can often be the last-line of defense against resistant microbes, we play an important role in ensuring their responsible production and stable and reliable supply.

We also recognize that it is only by collaborating across countries and industries, and by taking action together that we can start to make a positive difference. As such, the signing of this Declaration validates our ongoing commitment to the manufacture of critical antibiotics and unites us with our peers in working towards the single goal of beating antimicrobial resistance, to protect patients worldwide."

The Declaration calls for greater government cooperation with industry to develop alternative market structures that provide more sustainable and predictive models for antibiotics, vaccines and diagnostics. It also highlights the need for responsible, precise use of existing and new treatments, and for revitalization of innovative discovery and development to create the next generation of life-saving antibiotics.

In signing the Declaration, Xellia supports antimicrobial stewardship to help slow the rise in AMR and preserve the long-term effectiveness of existing antibiotics.

Xellia has a long heritage in producing anti-infectives. The Company has an extensive portfolio of key specialty anti-infectives, and is further expanding its production capabilities to help ensure a continued supply. Xellia is also working to provide new antibacterial treatment options by improving the efficacy, safety and delivery of existing anti-infectives, and has early-stage R&D projects dedicated to the discovery and formulation of new chemical entities effective against resistant microbes, with novel modes of action.

View the Declaration here: <http://www.ifpma.org/resource-centre/declaration-by-the-pharmaceutical-biotechnology-and-diagnostics-industries-on-combating-antimicrobial-resistance/>

- Ends –

**For more information, please contact:**

**Xellia Pharmaceuticals**

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

**Instinctif Partners (media relations)**

Melanie Toyne-Sewell / Eileen Paul / Jen Lewis

Tel: +44 (0)1260 296 500

Email: [xellia@instinctif.com](mailto:xellia@instinctif.com)

**About the Davos Declaration on Combatting Antimicrobial Resistance**

The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance marks a major step forward in the global battle against the growing problem of AMR. It reflects and welcomes the progress towards a comprehensive global response to AMR made by governments over the past 30 months in major multilateral forums including the World Health Organization (WHO) and the G7, and the contribution to these efforts provided by the work of the Review on AMR and other key international organisations.

**About Xellia**

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,300 people.

Xellia has a portfolio of specialty anti-infectives, and is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species.

Many of these are last resort antibiotics, often used when all other treatments have failed. Xellia is also dedicated to providing new anti-infective treatment options by improving the efficacy and delivery, and reducing toxic side effects of existing products. The Company also has early stage R&D programs focused on the discovery and formulation of new chemical entities effective against resistant microbes, with novel modes of action.

Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.

Further information about Xellia can be found at: [www.xellia.com](http://www.xellia.com).